ライフサイエンスコーパス: cyclooxygenase-2 inhibitor

1 d be decreased by treatment with a selective cyclooxygenase-2 inhibitor.

2 and this induction could be antagonized by a cyclooxygenase-2 inhibitor.

3 ncreased cardiovascular risk associated with cyclooxygenase-2 inhibitors.

4 astrointestinal safety outcomes of selective cyclooxygenase-2 inhibitors.

5 retinoids, statins, and tyrosine kinase and cyclooxygenase-2 inhibitors.

6 These effects were suppressed by a cyclooxygenase-2 inhibitor, a drug type known to reduce

7 ntake; administration of NS-398, a selective cyclooxygenase-2 inhibitor, abolished the arterial press

8 emity edema, and hypertension indicates that cyclooxygenase-2 inhibitors affect the kidney in a manne

9 Wild-type mice or human volunteers taking cyclooxygenase-2 inhibitors also showed increased plasma

10 onstatin cholesterol-lowering medications or cyclooxygenase 2 inhibitors and the development of TAO.

11 ogy; however, simultaneous administration of cyclooxygenase-2 inhibitors and dietary hen egg-white ly

12 uding newer N-methyl-D-asparate antagonists, cyclooxygenase-2 inhibitors and membrane stabilizing ana

13 ing other agents with NSAID-like mechanisms (cyclooxygenase-2 inhibitors and salicylates).

14 Newly developed drugs, such as selective cyclooxygenase-2 inhibitors and soluble tumor necrosis f

15 provided evidence that aspirin, celecoxib, (cyclooxygenase-2 inhibitor), and statins (3-hydroxy-3-me

16 atins, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and aspirin on colorectal c

17 Mast cell stabilizers, cyclooxygenase-2 inhibitors, and PGE2 receptor antagonis

18 ased risk associated with the use of certain cyclooxygenase-2 inhibitors, and randomized trial data s

19 The anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins may expand thei

20 f the anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins, may lead to th

21 r events has been demonstrated with multiple cyclooxygenase-2 inhibitors, and this increased risk has

22 Selective cyclooxygenase-2 inhibitors are as effective as nonselec

23 The European Medicines Agency concluded that cyclooxygenase-2 inhibitors are contraindicated in patie

24 oidal anti-inflammatory drugs) and selective cyclooxygenase-2 inhibitors are generating interest beca

25 However, these new selective cyclooxygenase-2 inhibitors are not risk free, and care

26 Cyclooxygenase-2 inhibitors are potent anti-inflammatory

27 L-4 since treating UV-irradiated mice with a cyclooxygenase-2 inhibitor blocked its production.

28 A specific cyclooxygenase-2 inhibitor blocked the formation of thre

29 phages with indomethacin, a cyclooxygenase-1/cyclooxygenase-2 inhibitor, blocked PGE(2) production.

30 For example, selective cyclooxygenase-2 inhibitors can provide the same symptom

31 A recent study showing that celecoxib, a cyclooxygenase-2 inhibitor, can alter the natural histor

32 reliminary data suggested that the selective cyclooxygenase -2 inhibitor celecoxib (CBX) might enhanc

33 e antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI

34 Treatment with a cyclooxygenase 2 inhibitor celecoxib significantly impro

35 Systemic administration of the cyclooxygenase 2 inhibitor celecoxib suppressed both PGE

36 tion with arachidonic acid and the selective cyclooxygenase-2 inhibitor celecoxib.

37 1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose che

38 Treatment with a selective cyclooxygenase-2 inhibitor, celecoxib, markedly inhibite

39 linical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib.

40 d gliosis were assessed in pups treated with cyclooxygenase-2 inhibitor compared to controls at Day 1

41 increased risk associated with a variety of cyclooxygenase-2 inhibitors compared with either a tradi

42 roidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors consistently reduce postoper

43 iovascular risks of treatment with selective cyclooxygenase 2 inhibitors (coxibs) and nonselective no

44 ular risks associated with anti-inflammatory cyclooxygenase 2 inhibitors (coxibs) by targeting the pr

45 Cyclooxygenase-2 inhibitors (coxibs) are characterized b

46 Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for

47 Although cyclooxygenase-2 inhibitors (coxibs) were developed to c

48 ted to an 'imbalance theory' suggesting that cyclooxygenase-2 inhibitors create an 'imbalance' betwee

49 Lumiracoxib is a selective cyclooxygenase-2 inhibitor developed for the symptomatic

50 Cardiovascular side effects associated with cyclooxygenase-2 inhibitor drugs dominate clinical conce

51 /2 randomized clinical trial (TBCOX2) of the cyclooxygenase-2 inhibitor etoricoxib.

52 tudies indicated that celecoxib, a selective cyclooxygenase-2 inhibitor, exhibits potent antitumor ac

53 may be an important alternative to selective cyclooxygenase-2 inhibitors for patients who need aspiri

54 ophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, gabapentinoids, and ketamin

55 ophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, gabapentinoids, ketamine, p

56 epidermal growth factor receptor inhibitors, cyclooxygenase-2 inhibitors, green tea extract, and pero

57 t concentrations (1-2 microM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct eff

58 ds, non-steriodal antiinflammatory drugs and cyclooxygenase-2 inhibitors have been shown not to impac

59 ors for a nonselective NSAID and a selective cyclooxygenase 2 inhibitor in a double-blind outcomes tr

60 d clarify the true benefits of perioperative cyclooxygenase-2 inhibitors in acute pain management str

61 y justification for using the more expensive cyclooxygenase-2 inhibitors in preference to nonsteroida

62 tion of epidermal growth factor receptor and cyclooxygenase-2 inhibitors in SCCHN is warranted.

63 controversy surrounding the proper place of cyclooxygenase-2 inhibitors in the hierarchy of treatmen

64 udies have demonstrated an important role of cyclooxygenase-2 inhibitors in the management of acute p

65 increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecoxib.

66 studies, one may conclude that perioperative cyclooxygenase-2 inhibitors, in standard doses, decrease

67 The data comparing the cyclooxygenase-2 inhibitors is difficult to interpret be

68 -daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduc

69 tamin D, other 5-alpha-reductase inhibitors, cyclooxygenase-2 inhibitors, lycopene, and green tea.

70 demiologic and molecular evidence also makes cyclooxygenase-2 inhibitors, lycopene, soy, and green te

71 Cyclooxygenase-2 inhibitors may also reduce colorectal p

72 Concerns have been raised that cyclooxygenase-2 inhibitors may increase thrombotic card

73 Rofecoxib, but perhaps not all cyclooxygenase-2 inhibitors, may be associated with incr

74 that target enzymes in the cascade, such as cyclooxygenase 2 inhibitors, might be candidate treatmen

75 This IPDT agent integrates a celecoxib (cyclooxygenase-2 inhibitor) moiety with a near-infrared

76 ith dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammat

77 In previous work, the cyclooxygenase-2 inhibitor NS-398 inhibited interleukin

78 pression and activity and was blocked by the cyclooxygenase-2 inhibitors NS-398 and Resveratrol.

79 t of cAMP were inhibited only by a selective cyclooxygenase-2 inhibitor, NS-398.

80 The cyclooxygenase-2 inhibitor NS398 blocked PPARgamma-induc

81 or 30 mg/kg (high dose) of a known selective cyclooxygenase-2 inhibitor (NS398).

82 y simultaneous adolescent treatment with the cyclooxygenase-2 inhibitor, NS398.

83 studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in pati

84 prescription NSAIDs, particularly selective cyclooxygenase 2 inhibitors (OR = 0.38, 95% CI: 0.25, 0.

85 e treated with either rofecoxib (a selective cyclooxygenase-2 inhibitor) or indomethacin (a non-selec

86 Cyclooxygenase-2 inhibitors, or coxibs, designed to prov

87 (1 mg/kg intraperitoneally) or the selective cyclooxygenase-2 inhibitor parecoxib (20 mg/kg intraperi

88 In contrast, the cyclooxygenase-2 inhibitor parecoxib did not affect the

89 The potential thrombogenic risk of cyclooxygenase-2 inhibitors remains controversial, and c

90 reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every mornin

91 is antiapoptotic effect was inhibited by the cyclooxygenase-2 inhibitor rofecoxib and was restored by

92 a protective strategy such as the selective cyclooxygenase 2 inhibitor, rofecoxib, to avert a clinic

93 of 4T1-tumor-bearing wild-type mice with the cyclooxygenase 2 inhibitor, SC58236, delays primary tumo

94 exposure and chemoprevention, possibly with cyclooxygenase 2 inhibitors, should reduce the incidence

95 us to demonstrate that pain was blocked by a cyclooxygenase-2 inhibitor, suggesting an indirect effec

96 roidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors that block prostanoid synthe

97 ho initiated nonselective NSAID or selective cyclooxygenase 2 inhibitor therapy between January 1, 19

98 -year nonvertebral fracture risk, a study of cyclooxygenase 2 inhibitors versus nonselective nonstero

99 e of nonsteroidal anti-inflammatory drug and cyclooxygenase-2 inhibitor was associated with a reduced

100 Prolonged use of cyclooxygenase-2 inhibitors was minimal, but for those r

101 A novel class of NSAIDs, cyclooxygenase-2 inhibitors, was introduced in 1999.

102 Selective cyclooxygenase-2 inhibitors were developed to reduce the

103 This is exemplified by the clinical use of cyclooxygenase 2 inhibitors, which interfere with PGE2 s

104 emotherapeutic agents suggest that combining cyclooxygenase-2 inhibitors with other agents may have s

105 al studies combining antiangiogenic drugs or cyclooxygenase-2 inhibitors with PDT show improved treat

106 multimodal techniques, for example combining cyclooxygenase-2 inhibitors with regional blocks, may he

107 findings led to the development of selective cyclooxygenase-2 inhibitors, with comparable anti-inflam